HALO Halozyme Therapeutics, Inc.

+0  (3%)
Previous Close 12.82
Open 12.89
Price To book 0.00
Market Cap 1.70B
Shares 128,198,000
Volume 810,766
Short Ratio 18.30
Av. Daily Volume 1,341,950

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA June 26, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 enrollment closed due to lack of efficacy.
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017.
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Approved September 12, 2014.
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 2 topline data released 1Q 2014

Latest News

  1. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April 21, 2017
  2. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  3. Halozyme To Host First Quarter 2017 Financial Results Conference Call
  4. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April 6, 2017
  5. Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models
  6. Rosetta Genomics and Halozyme Therapeutics: Wait for Better News
  7. Here's Why Halozyme Therapeutics, Inc Is Falling
  8. Biotech Premarket Movers: Halozyme, Omeros, Aralez
  9. Halozyme Provides Update On SWOG Collaborative Group Clinical Study
  10. ETFs with exposure to Halozyme Therapeutics, Inc. : March 30, 2017
  11. FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology
  12. Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
  13. 5 Small-Cap Biotech Stocks to Buy in March
  14. Edited Transcript of HALO earnings conference call or presentation 28-Feb-17 9:30pm GMT
  15. Halozyme Therapeutics reports 4Q loss
  16. Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results
  17. Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season
  18. Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
  19. MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20